Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

PaperCitations, authors & open-access status

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 304 citations, 2022 year and hybrid oa status.

304
Citations
2022
Year
hybrid
OA Status

Related on ScholarIQ

Hugh J. McMillan
Author
Nature Medicine
Journal
Neurogenetic and Muscular Disorders Research
Topic
Neurogenetic and Muscular Disorders Research
Topic
RNA modifications and cancer
Topic
Congenital Anomalies and Fetal Surgery
Topic
470M+ articles · free account